Contrast agent for adults having brain or spinal cord MRI scans
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new contrast agent (a dye injected before an MRI) to see how well it works for people having brain or spinal cord scans. It aims to improve image quality so doctors can see lesions more clearly, which may help with diagnosis and treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a known or highly suspected brain or spinal cord problem that shows up as a spot on an MRI scan.
- You are scheduled for a contrast-enhanced MRI and are willing to have two such scans.
- You do not have moderate to severe kidney problems (glomerular filtration rate less than 60).
- You can safely have an MRI, meaning no metal implants and no severe claustrophobia.
- You have no history of severe allergies to drugs or contrast agents.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new contrast agent called mangaciclanol for MRI scans of the central nervous system (brain and spine) or body areas like the chest, belly, pelvis, and muscles. You may join if you have known or suspected tumors that need an MRI with contrast, and you're healthy enough to have two contrast MRIs within a short time.
This trial compares two contrasting dyes (gadopiclenol and gadobutrol) used during pituitary MRI scans to see which one provides clearer images. It is for adults with known or suspected pituitary lesions that disrupt the blood-brain barrier.
This trial tests whether two special MRI contrast medicines—gadolinium and ferumoxytol—can better diagnose problems in the brain or central nervous system. It may help doctors identify what’s causing symptoms or abnormal brain findings.
This trial uses a new type of MRI contrast dye (USPIO) to get clearer images of certain slow-growing brain tumors (vestibular schwannomas and low-grade gliomas). The goal is to see if this dye helps doctors better understand and treat these tumors.
This trial tests whether a newer contrast agent, gadopiclenol, works as well as the standard one for liver scans. It might be an option if you need an MRI to check for liver disease, tumors, or treatment response.
This study looks at whether getting the MRI contrast dye multiple times over 5 years affects body movement and thinking skills. It compares people who had the dye repeatedly with people who have little or no exposure, using brain MRI scans and regular mental and movement testing.
Hear when a new For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.